PRMT5 and lung carcinoma: Interestingly, in our previous report, we demonstrated that PRMT6 asymmetrically dimethylates the R9 and R372 sites of ENO1 in lung cancer,51 which is different from our finding in this study that PRMT5 only symmetrically dimethylates the R9 site of ENO1 in ovarian cancer.